drugset / Trial / NCT02626715

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

NCT02626715

Phase 2 Completed 21 enrolled Randy Windreich
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare safety and efficacy of reduced-intensity conditioning and myeloablative conditioning regimens prior to HSCT in high-risk AML/MDS pediatric and young adult patients. This study investigates the use of two novel conditioning therapies for hematopoietic stem cell transplant (HSCT). The primary focus of both the investigators' myeloablative and reduced-intensity conditioning regimens is to reduce overall toxicity so that pediatric and young adult patients with high-risk AML/MDS with significant pretransplant comorbidities who would have been ineligible to proceed to HSCT previously can now receive potentially life-saving treatment.

Timeline

Start
2015-09-04
Primary completion
2023-04-12
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Busulfan Small molecule
Comparator Hydroxyurea Other / unclassified
Comparator Melphalan Small molecule
Comparator Alemtuzumab Monoclonal antibody
Comparator Fludarabine Small molecule
Comparator Thiotepa Other / unclassified